Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that ritlecitinib effectively improved hair regrowth in JAK inhibitor-naïve adolescent patients with severe alopecia areata, achieving significant reductions in SALT scores within 24 weeks, but was less effective for patients who had previously been treated with baricitinib.

In a preclinical mouse model, this study found that early treatment with the selective SYK inhibitor entospletinib significantly improved survival rates and clinical outcomes for graft-versus-host disease after hematopoietic stem cell transplantation compared to placebo.

This study found that KAP and KRTAP genes positively correlate with the cashmere growth cycle, and their regulation aligns with the growth phases of cashmere in secondary hair follicles.

This study introduced a single-stage network using large kernel attention that effectively restores high-resolution images by capturing both global and local details, reducing parameters and improving processing speed.

This study reported a drug-induced pityriasis rubra pilaris-like eruption in a patient treated with sorafenib, suggesting a possible effect of sorafenib on keratinocyte biology.

This study found that phenyl-imidazole sulfonamide derivatives, particularly ISCK03, inhibited c-kit signaling and promoted depigmentation in various experimental settings, suggesting potential use as skin-whitening agents.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This bibliography catalogues 335+ publications produced using the N-K Model over 13 months and reports no new scientific results.

This study found that patients with alopecia areata and androgenetic alopecia showed increased c-kit expression and decreased Ki-67 expression in hair follicle cells compared to controls, suggesting a possible feedback mechanism involving stem cell factor signaling.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This study showed that the zinc finger protein GIS3 is important for root hair growth in Arabidopsis by regulating RHD2 and RHD4 genes, with application of ethylene and cytokinin helping restore root hair presence in mutated variants.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

This dissertation proposes a framework for analyzing medical images on mobile devices but presents no new research findings, focusing instead on development methodologies and their applications to hair transplant and glaucoma contexts.

In this study, water-soluble recombinant keratins, specifically RK81, were developed and used in microneedles to investigate their effect on hair growth, discovering that more than 40% of the hair follicles responded, demonstrating the potential for hair growth promotion.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This study developed a multipurpose herbal gel formulation that enhances hair manageability, provides antimicrobial benefits, and supports skin care. The gel is non-irritating, leaves hair soft, and imparts a glow to the skin while being cost-effective.

This abstract provides a graphic illustrating that mice lacking the Sgk3 gene exhibit thin coats and abnormal hair, suggesting a role for Sgk3 kinase in hair follicle growth, but reports no new experimental findings.

This study found that topical ruxolitinib protected Lgr5+ skin stem cells and maintained skin homeostasis in skin GVHD, unlike corticosteroids.

This study evaluated krokot extract as a hair tonic and found it to be microbiologically safe, effective at extending and increasing hair weight, non-irritating, and generally well-received in terms of aroma and color when tested on rabbits.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This study introduces Kalya Research, an AI-driven tool designed to identify and categorize literature on complementary and alternative medicines, showing its effectiveness compared to Medline in finding relevant alopecia research within the context of breast cancer patients.